Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

American Journal of Psychiatry

Volumn 155, Issue 7, 1998, Pages 914-920

  Conley, Robert R ^a   Tamminga, Carol A ^b   Bartko, John J ^b   Richardson, Charles ^b   Peszke, Michael ^b   Lingle, Jami ^b   Hegerty, Judith ^b   Love, Raymond ^b   Gounaris, Cathy ^b   Zaremba, Sandra ^b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AKATHISIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0031748732     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.7.914     Document Type: Article

References (26)

1. Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23:663-674
2. Prien RF, Cole JO: High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18:482-95
3. Davis JM, Casper R: Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1977; 12:260-282
4. Essock SM, Hargreaves W A, Dohm FA, Goethe J, Carver L, Hipshman L: Clozapine eligibility among state hospital patients. Schizophr Bull 1996; 22:15-25
5. McGlashan TH: A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14:515-542
6. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA: Economic grand rounds: cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41:850-854
7. Christison GW, Kirch DG, Wyatt RJ: When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17:217-245
8. Barnes TRE, McEvedy CJB: Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol 1996; 11:67-71
9. Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
10. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
11. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
12. Conley RR, Carpenter WT Jr, Tamminga CA: Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154: 1243-1247
13. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P: Treatment of neuroleptic-resistant schizophrenia relapse. Psychopharmacol Bull 1993; 29:309-314
14. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW: Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996; 124:87-94
15. Robertson GS, Fibiger HC: Effects of olanzapine on regional Cfos expression in rat forebrain. Neuropsychopharmacology 1996; 14:109-110
16. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
17. Simpson GM, Varga E: Ciozapine: a new and unusual antipsychotic agent. Psychopharmacol Bull 1975; 11:14-15
18. Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1987
19. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
20. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
21. Conley R, Zaremba S, McMullen R, Love R: Evaluating ability to consent in psychotic inpatients (abstract). Schizophr Res 1997; 24:206
22. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
23. Simpson GM, Angus JWS: A rating scale for extrpyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
24. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
25. Dixon WJ (ed): BMPD Statistical Software Manual, vol 2. Berkeley, University of California Press, 1992
26. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752